Compare FNWD & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | ADCT |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.7M | 136.1M |
| IPO Year | 1996 | 2019 |
| Metric | FNWD | ADCT |
|---|---|---|
| Price | $43.26 | $1.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $37.50 | $7.75 |
| AVG Volume (30 Days) | 10.5K | ★ 1.5M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | $17.40 | N/A |
| Revenue Next Year | $5.44 | $66.49 |
| P/E Ratio | $43.03 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $30.05 | $0.78 |
| 52 Week High | $45.90 | $4.98 |
| Indicator | FNWD | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 48.95 |
| Support Level | $36.08 | $1.03 |
| Resistance Level | $45.90 | $1.20 |
| Average True Range (ATR) | 0.56 | 0.08 |
| MACD | -0.46 | 0.02 |
| Stochastic Oscillator | 14.95 | 57.00 |
Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).